Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Daiichi Sankyo
< Previous
1
2
Next >
Daiichi Sankyo Unveils New Research Across Industry-Leading ADC Portfolio in Multiple Cancers at WCLC and ESMO
Today 8:00 EDT
From
Daiichi Sankyo
Via
Business Wire
ENHERTU® Granted Breakthrough Therapy Designation in U.S. for Certain Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer
August 19, 2024
From
Daiichi Sankyo
Via
Business Wire
Daiichi Sankyo and Merck Enter into Global Development and Commercialization Agreement for MK-6070
August 06, 2024
From
Daiichi Sankyo
Via
Business Wire
Tickers
MRK
IDeate-Lung02 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Relapsed Small Cell Lung Cancer
August 01, 2024
From
Daiichi Sankyo
Via
Business Wire
Tickers
MRK
Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer
June 26, 2024
From
Daiichi Sankyo
Via
Business Wire
Tickers
MRK
Datopotamab Deruxtecan Showed Clinically Meaningful Overall Survival Improvement Versus Chemotherapy in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial
May 27, 2024
From
Daiichi Sankyo
Via
Business Wire
Daiichi Sankyo Highlights Progress in Creating New Standards of Care for Patients Across Multiple Cancers at ASCO
May 21, 2024
From
Daiichi Sankyo
Via
Business Wire
ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
April 29, 2024
From
Daiichi Sankyo
Via
Business Wire
ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors
April 05, 2024
From
Daiichi Sankyo
Via
Business Wire
Tickers
AZN
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
April 03, 2024
From
Daiichi Sankyo
Via
Business Wire
Tickers
MRK
ENHERTU® Granted Priority Review in the U.S. for Patients with Metastatic HER2 Positive Solid Tumors
January 29, 2024
From
Daiichi Sankyo
Via
Business Wire
Patritumab Deruxtecan Granted Priority Review in the U.S. for Certain Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
December 22, 2023
From
Daiichi Sankyo
Via
Business Wire
Tickers
MRK
Two Phase 3 Trials of Datopotamab Deruxtecan Plus Durvalumab Initiated in Patients Across Two Breast Cancer Subtypes
December 18, 2023
From
Daiichi Sankyo
Via
Business Wire
Daiichi Sankyo Demonstrates Breadth and Depth of Oncology Portfolio Across Multiple Cancers with New Data at ESMO Asia, SABCS and ASH
December 01, 2023
From
Daiichi Sankyo
Via
Business Wire
ENHERTU® Demonstrated Clinically Meaningful Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trial
October 23, 2023
From
Daiichi Sankyo
Via
Business Wire
Datopotamab Deruxtecan Improved Progression-Free Survival Versus Chemotherapy in Patients with Previously Treated Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial
October 23, 2023
From
Daiichi Sankyo
Via
Business Wire
Datopotamab Deruxtecan Significantly Extended Progression-Free Survival Versus Chemotherapy in Patients with HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial
October 23, 2023
From
Daiichi Sankyo
Via
Business Wire
Datopotamab Deruxtecan Plus Durvalumab Demonstrated Robust and Durable Tumor Responses in First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer in BEGONIA Phase 1b/2 Trial
October 22, 2023
From
Daiichi Sankyo
Via
Business Wire
Daiichi Sankyo and Merck Announce Global Development and Commercialization Collaboration for Three Daiichi Sankyo DXd ADCs
October 19, 2023
From
Daiichi Sankyo
Via
Business Wire
Tickers
MRK
Daiichi Sankyo Showcases Progress in Developing New Standards of Care for Patients with Industry-Leading DXd ADC Portfolio Across Multiple Cancers at ESMO
October 16, 2023
From
Daiichi Sankyo
Via
Business Wire
Datopotamab Deruxtecan Demonstrated Statistically Significant and Clinically Meaningful Progression-Free Survival Benefit in Patients with HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial
September 22, 2023
From
Daiichi Sankyo
Via
Business Wire
ENHERTU® Demonstrated Strong and Durable Tumor Responses in Previously Treated HER2 Mutant Advanced Lung Cancer in DESTINY-Lung02 Phase 2 Trial
September 11, 2023
From
Daiichi Sankyo
Via
Business Wire
Datopotamab Deruxtecan Plus Durvalumab Showed Promising Clinical Activity in the First-Line Advanced Non-Small Cell Lung Cancer Setting in TROPION-Lung04 Phase 1b Trial
September 10, 2023
From
Daiichi Sankyo
Via
Business Wire
Ifinatamab Deruxtecan Continues to Demonstrate Durable Responses in Patients with Advanced Small Cell Lung Cancer in Early Trial
September 10, 2023
From
Daiichi Sankyo
Via
Business Wire
Patritumab Deruxtecan Demonstrated Clinically Meaningful and Durable Responses in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer in HERTHENA-Lung01 Phase 2 Trial
September 10, 2023
From
Daiichi Sankyo
Via
Business Wire
DS-3939 Enters Clinical Development in Patients Across Several Types of Advanced Solid Cancers
September 07, 2023
From
Daiichi Sankyo
Via
Business Wire
ENHERTU® Granted Two Breakthrough Therapy Designations in U.S. for Patients Across Multiple HER2 Expressing Cancers
August 31, 2023
From
Daiichi Sankyo
Via
Business Wire
Daiichi Sankyo Highlights Progress in Creating New Standards of Care for Patients with Lung Cancer with Data Across DXd ADC Portfolio at WCLC
August 16, 2023
From
Daiichi Sankyo
Via
Business Wire
VANFLYTA® Now Available in U.S. for Patients with Newly Diagnosed FLT3-ITD Positive AML
August 09, 2023
From
Daiichi Sankyo
Via
Business Wire
ENHERTU® Demonstrated Clinically Meaningful Progression-Free Survival and Overall Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trial
July 27, 2023
From
Daiichi Sankyo
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.